Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E.
Target Price
The average target price of ALTHX.PA is 5.8 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell